Elevated Kallikrein 7 Expression Tied to Itch in Atopic Dermatitis
An emerging paradigm in itch biology is supported by findings that suggest KLK7 as an influence in the disease pathogenesis of atopic dermatitis.
Pruritus
PIQ Short Forms Show Good Validity in Assessment of Itch in Adults With AD
The new Patient-Reported Outcomes Measurement Information System (PROMIS) Itch Questionnaire (PIQ) short forms may have application in clinical trial and practice.
Habit Reversal Training for Trichotillomania, Excoriation Disorder, and Itch
Katlein França, MD, PhD, spoke with Dermatology Advisor about the use of the behavior therapy technique “habit reversal training” (HRT) for the treatment of trichotillomania, excoriation disorder, and itch.
Pathophysiology and Management of Sensitive Skin: Lack of Study Data Limits Consensus
Patients with sensitive skin require a personalized approach that takes into account the various possible biomedical, neural, and psychosocial factors that may be responsible.
Family Constellation Seminars Reduce Itch Associated With Atopic Dermatitis, Psoriasis
Participation in 4 therapy seminars resulted in appreciable improvement in pruritus in patients with atopic dermatitis or psoriasis and may be an efficient supplementary method for managing chronic itch in these populations.
Difelikefalin Improves Itch in Hemodialysis-Linked Pruritus
For patients undergoing hemodialysis who have moderate-to-severe pruritus, difelikefalin is associated with a significant reduction in itch intensity and improvement in itch-related quality of life.
Tofacitinib Effective in Treatment of Chronic Pruritus With Rheumatoid Arthritis
Investigators evaluated the treatment of chronic pruritus with tofacitinib in patients with concomitant rheumatoid arthritis.
Dupilumab Induces Rapid Improvement of Atopic Dermatitis in Japanese Adults
Data from this analysis indicate that dupilumab induces rapid improvements in AD that can be maintained long term in a significant percentage of Japanese adults with moderate to severe AD, with prolonged benefits in terms of both pruritus and QoL.
NK1 Receptor Antagonist May Reduce Itching in Epidermolysis Bullosa
This phase 2 serlopitant study is the first randomized clinical trial for EB-related pruritus demonstrating safety and potential itch reduction.
Transitioning Patients: Medical and Aesthetic Recommendations for Dermatologists
A review of the unique transition-related medical and aesthetic dermatologic needs of patients undergoing transition.
Next post in Acne
